Annexon (ANNX) Competitors $2.06 +0.09 (+4.57%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$2.06 +0.00 (+0.24%) As of 05/22/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. NRIX, XERS, BCAX, OCS, RCKT, CYCC, NAGE, VIR, AVXL, and NUVBShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Nurix Therapeutics (NRIX), Xeris Biopharma (XERS), Bicara Therapeutics (BCAX), Oculis (OCS), Rocket Pharmaceuticals (RCKT), Cyclacel Pharmaceuticals (CYCC), Niagen Bioscience (NAGE), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Nurix Therapeutics Xeris Biopharma Bicara Therapeutics Oculis Rocket Pharmaceuticals Cyclacel Pharmaceuticals Niagen Bioscience Vir Biotechnology Anavex Life Sciences Nuvation Bio Annexon (NASDAQ:ANNX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation. Which has stronger earnings & valuation, ANNX or NRIX? Annexon has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$134.24M-$1.18-1.75Nurix Therapeutics$56.42M13.50-$193.57M-$2.80-3.57 Does the MarketBeat Community favor ANNX or NRIX? Nurix Therapeutics received 29 more outperform votes than Annexon when rated by MarketBeat users. Likewise, 78.18% of users gave Nurix Therapeutics an outperform vote while only 78.08% of users gave Annexon an outperform vote. CompanyUnderperformOutperformAnnexonOutperform Votes5778.08% Underperform Votes1621.92% Nurix TherapeuticsOutperform Votes8678.18% Underperform Votes2421.82% Which has more risk and volatility, ANNX or NRIX? Annexon has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Is ANNX or NRIX more profitable? Annexon has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -354.85%. Annexon's return on equity of -38.99% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -38.99% -33.90% Nurix Therapeutics -354.85%-53.65%-38.59% Does the media refer more to ANNX or NRIX? In the previous week, Annexon and Annexon both had 14 articles in the media. Nurix Therapeutics' average media sentiment score of 1.24 beat Annexon's score of 0.53 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ANNX or NRIX? Annexon currently has a consensus price target of $12.50, indicating a potential upside of 506.80%. Nurix Therapeutics has a consensus price target of $30.44, indicating a potential upside of 204.75%. Given Annexon's stronger consensus rating and higher possible upside, research analysts plainly believe Annexon is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.84 SummaryAnnexon beats Nurix Therapeutics on 8 of the 14 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$226.01M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-1.969.0626.7119.71Price / SalesN/A251.51386.08120.53Price / CashN/A65.8538.2534.62Price / Book0.646.456.774.50Net Income-$134.24M$143.98M$3.23B$248.22M7 Day Performance2.49%0.38%0.48%-0.78%1 Month Performance11.96%2.14%9.10%11.53%1 Year Performance-56.17%-0.33%18.56%8.99% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon1.8657 of 5 stars$2.06+4.6%$12.50+506.8%-57.8%$226.01MN/A-1.9660NRIXNurix Therapeutics2.3949 of 5 stars$10.18+7.2%$30.44+199.1%-38.0%$776.08M$56.42M-3.52300Positive NewsAnalyst DowngradeGap UpXERSXeris Biopharma4.5497 of 5 stars$4.95-1.2%$6.25+26.3%+142.8%$774.11M$203.07M-11.00290Analyst DowngradeBCAXBicara Therapeutics1.6485 of 5 stars$14.19+9.4%$32.43+128.5%N/A$773.87MN/A0.0032News CoveragePositive NewsAnalyst DowngradeAnalyst RevisionGap UpOCSOculis2.2464 of 5 stars$17.60-5.3%$31.50+79.0%+50.8%$768.45M$980,000.00-9.122RCKTRocket Pharmaceuticals4.9044 of 5 stars$7.00+0.1%$40.82+483.1%-70.8%$747.50MN/A-2.55240Positive NewsCYCCCyclacel Pharmaceuticals0.4411 of 5 stars$3.59-11.5%N/A-95.8%$744.34M$43,000.00-0.3814NAGENiagen BioscienceN/A$9.39+4.9%N/AN/A$738.84M$99.60M55.24120News CoverageVIRVir Biotechnology2.9107 of 5 stars$5.30+4.1%$32.86+519.9%-59.5%$731.74M$14.30M-1.35580News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAVXLAnavex Life Sciences3.8615 of 5 stars$8.55+3.6%$44.00+414.6%+70.4%$729.93MN/A-15.5540NUVBNuvation Bio3.7142 of 5 stars$2.15+2.6%$7.83+265.2%-31.6%$726.47M$7.87M-0.9960Positive NewsGap Up Related Companies and Tools Related Companies NRIX Competitors XERS Competitors BCAX Competitors OCS Competitors RCKT Competitors CYCC Competitors NAGE Competitors VIR Competitors AVXL Competitors NUVB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANNX Stock Free ANNX Stock Alerts